{"id":3121,"date":"2017-04-28T15:25:59","date_gmt":"2017-04-28T19:25:59","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\/"},"modified":"2026-09-24T00:09:57","modified_gmt":"2026-09-24T04:09:57","slug":"gensight-biologics-met-a-disposition-son-document-de-reference-2016","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/28\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\/","title":{"rendered":"GenSight Biologics met \u00e0 disposition son Document  de R\u00e9f\u00e9rence 2016"},"content":{"rendered":"\n<strong>Paris, \u00a028 avril \u00a02017, 20h00 CET \u2013<\/strong> GenSight Biologics (Euronext : SIGHT, FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui avoir mis \u00e0 la disposition du public son Document de R\u00e9f\u00e9rence 2016 en langue anglaise, enregistr\u00e9 par l\u2019Autorit\u00e9 des march\u00e9s financiers (AMF) en date du 28 avril 2017 sous le num\u00e9ro R-17-36.\n\nLe document de r\u00e9f\u00e9rence inclut notamment :\n<ul>\n \t<li>le rapport financier annuel 2016 ;<\/li>\n \t<li>le rapport de gestion ;<\/li>\n \t<li>le rapport \u00a0du \u00a0Pr\u00e9sident du \u00a0Conseil d\u2019administration sur \u00a0le \u00a0gouvernement d\u2019entreprise, les proc\u00e9dures de contr\u00f4le interne et de gestion des risques ; et<\/li>\n \t<li>le descriptif du programme de rachat d\u2019actions.<\/li>\n<\/ul>\nCe \u00a0document \u00a0de \u00a0r\u00e9f\u00e9rence \u00a0peut \u00a0\u00eatre \u00a0consult\u00e9 \u00a0sur \u00a0le \u00a0site \u00a0internet \u00a0de \u00a0la \u00a0Soci\u00e9t\u00e9 \u00a0\u00e0 \u00a0l\u2019adresse <a href=\"https:\/\/www.gensight-biologics.com\/\">www.gensight-biologics.com, <\/a>section Investisseurs, ainsi que sur le site de l\u2019AMF \u00e0 l\u2019adresse \u00a0<a href=\"http:\/\/www.amf-france.org\/\">www.amf- <\/a><a href=\"http:\/\/www.amf-france.org\/\">france.org. <\/a>Des exemplaires du Document de R\u00e9f\u00e9rence 2016 sont \u00e9galement disponibles gratuitement, sur demande, au si\u00e8ge social de la Soci\u00e9t\u00e9 situ\u00e9 74, rue du Faubourg Saint-Antoine, 75012 Paris, France.\n<h2>\u00c0 propos \u00a0de GenSight Biologics<\/h2>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (Mitochondrial Targeting Sequence, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, GS010, est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intravitr\u00e9enne dans chaque \u0153il.\n","protected":false},"excerpt":{"rendered":"<p>Paris, \u00a028 avril \u00a02017, 20h00 CET \u2013 GenSight Biologics (Euronext : SIGHT, FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui avoir mis \u00e0 la disposition du public son Document de R\u00e9f\u00e9rence [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[],"post-year":[],"class_list":["post-3121","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics met \u00e0 disposition son Document de R\u00e9f\u00e9rence 2016 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/28\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics met \u00e0 disposition son Document de R\u00e9f\u00e9rence 2016 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, \u00a028 avril \u00a02017, 20h00 CET \u2013 GenSight Biologics (Euronext : SIGHT, FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui avoir mis \u00e0 la disposition du public son Document de R\u00e9f\u00e9rence [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/28\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2017-04-28T19:25:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:09:57+00:00\" \/>\n<meta name=\"author\" content=\"editeur\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"editeur\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/28\\\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/28\\\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\\\/\"},\"author\":{\"name\":\"editeur\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"headline\":\"GenSight Biologics met \u00e0 disposition son Document de R\u00e9f\u00e9rence 2016\",\"datePublished\":\"2017-04-28T19:25:59+00:00\",\"dateModified\":\"2026-09-24T04:09:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/28\\\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\\\/\"},\"wordCount\":398,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/28\\\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/28\\\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\\\/\",\"name\":\"GenSight Biologics met \u00e0 disposition son Document de R\u00e9f\u00e9rence 2016 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2017-04-28T19:25:59+00:00\",\"dateModified\":\"2026-09-24T04:09:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/28\\\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/28\\\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/04\\\/28\\\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics met \u00e0 disposition son Document de R\u00e9f\u00e9rence 2016\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\",\"name\":\"editeur\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"caption\":\"editeur\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics met \u00e0 disposition son Document de R\u00e9f\u00e9rence 2016 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/28\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics met \u00e0 disposition son Document de R\u00e9f\u00e9rence 2016 - GenSight Biologics","og_description":"Paris, \u00a028 avril \u00a02017, 20h00 CET \u2013 GenSight Biologics (Euronext : SIGHT, FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui avoir mis \u00e0 la disposition du public son Document de R\u00e9f\u00e9rence [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/28\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\/","og_site_name":"GenSight Biologics","article_published_time":"2017-04-28T19:25:59+00:00","article_modified_time":"2026-09-24T04:09:57+00:00","author":"editeur","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"editeur","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/28\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/28\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\/"},"author":{"name":"editeur","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"headline":"GenSight Biologics met \u00e0 disposition son Document de R\u00e9f\u00e9rence 2016","datePublished":"2017-04-28T19:25:59+00:00","dateModified":"2026-09-24T04:09:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/28\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\/"},"wordCount":398,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/28\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/28\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\/","name":"GenSight Biologics met \u00e0 disposition son Document de R\u00e9f\u00e9rence 2016 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2017-04-28T19:25:59+00:00","dateModified":"2026-09-24T04:09:57+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/28\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/28\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/04\/28\/gensight-biologics-met-a-disposition-son-document-de-reference-2016\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics met \u00e0 disposition son Document de R\u00e9f\u00e9rence 2016"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a","name":"editeur","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","caption":"editeur"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3121"}],"version-history":[{"count":2,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3121\/revisions"}],"predecessor-version":[{"id":6408,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3121\/revisions\/6408"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3121"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3121"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3121"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3121"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}